Use of metabotropic receptor agonists in progressive neurodegenerative diseases
US5622981A · kind A · utility
3Cited by
3References
18Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 7, 1995 |
| Grant date | Apr 22, 1997 |
| Priority date | — |
| Expiry date | Apr 7, 2015 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K31/42
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A method of treating a mammal with a neurodegenerative disease which is caused at least in part by the neurotoxic effects of the .beta.-amyloid protein. This method constitutes administering a metabotropic receptor agonist to such a mammal. In particular, the agonist trans-ACPD or 1S,3R-ACPD can be administered intravenously to treat a mammal with Alzheimer's disease.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.